GRAIL, Inc. $GRAL Shares Purchased by JPMorgan Chase & Co.

Key Points

• JPMorgan Chase boosted its stake in GRAIL by 159.1% in Q3 to 206,120 shares (about 0.57%, ~$12.19M), and several other institutions (Geode, Allianz, Invesco, Carnegie, Caxton) also materially increased their positions.
• Analysts are mixed: GRAIL has a consensus "Hold" rating with a $90.17 target, while individual price targets range widely from $60 (Morgan Stanley) to $130 (Guggenheim) with three Buys, two Holds and one Sell.
• The company remains unprofitable despite beating EPS estimates for the quarter (EPS -$2.44 vs. -$3.33) and insiders sold about 64,079 shares over the last three months (insiders now own 1.85%).

JPMorgan Chase & Co. boosted its holdings in GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 159.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 206,120 shares of the company's stock after acquiring an additional 126,576 shares during the quarter. JPMorgan Chase & Co. owned about 0.57% of GRAIL worth $12,188,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of GRAIL by 60.4% in the 2nd quarter. Geode Capital Management LLC now owns 757,770 shares of the company's stock valued at $38,969,000 after purchasing an additional 285,331 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in GRAIL by 145.9% in the third quarter. Allianz Asset Management GmbH now owns 294,835 shares of the company's stock valued at $17,434,000 after buying an additional 174,959 shares in the last quarter. Invesco Ltd. boosted its stake in shares of GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company's stock worth $11,244,000 after acquiring an additional 157,780 shares in the last quarter. Carnegie Investment Counsel grew its holdings in shares of GRAIL by 48.1% in the 3rd quarter. Carnegie Investment Counsel now owns 245,315 shares of the company's stock worth $14,505,000 after acquiring an additional 79,630 shares during the period. Finally, Caxton Associates LLP acquired a new stake in shares of GRAIL in the 2nd quarter worth approximately $3,320,000.

Wall Street Analyst Weigh In

GRAL has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of GRAIL in a research note on Thursday, January 22nd. Robert W. Baird set a $82.00 target price on shares of GRAIL in a research report on Friday, February 20th. Guggenheim increased their price target on shares of GRAIL from $100.00 to $130.00 and gave the company a "buy" rating in a research report on Monday, January 26th. TD Cowen assumed coverage on shares of GRAIL in a research note on Thursday, February 19th. They set a "hold" rating and a $114.00 price objective for the company. Finally, Morgan Stanley lowered their target price on GRAIL from $110.00 to $60.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, GRAIL has a consensus rating of "Hold" and a consensus target price of $90.17.

Insider Activity at GRAIL

In other news, CFO Aaron Freidin sold 9,573 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $50.17, for a total value of $480,277.41. Following the completion of the sale, the chief financial officer directly owned 309,622 shares in the company, valued at approximately $15,533,735.74. The trade was a 3.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 37,504 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $50.17, for a total value of $1,881,575.68. Following the sale, the chief executive officer owned 650,525 shares in the company, valued at $32,636,839.25. The trade was a 5.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,079 shares of company stock valued at $3,214,673 over the last three months. 1.85% of the stock is owned by insiders.

GRAIL Price Performance

NASDAQ:GRAL opened at $51.80 on Friday. The firm has a market cap of $2.02 billion, a PE ratio of -4.63 and a beta of 5.18. The firm has a 50 day simple moving average of $89.73 and a 200-day simple moving average of $77.12. GRAIL, Inc. has a 1-year low of $20.44 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL - Get Free Report) last released its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.33) by $0.89. The firm had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. As a group, sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRAIL, Inc. (NASDAQ:GRAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.